NanoViricides, Inc. (NASDAQ:NNVC) | Finanzwire

Basculer en Français

10456	Companies
219586	Keywords
148965	Articles
116109	Press releases

Home
Companies
NanoViricides, Inc.

BRIEF

published on 05/26/2026 at 14:35, 1 hour 40 minutes ago

NanoViricides' NV-387 Prepared for Ebola Treatment Amidst Outbreak

NanoViricides NV-387 Public Health Antiviral Drug Ebola Outbreak
PRESS RELEASE

published on 05/26/2026 at 14:30, 1 hour 45 minutes ago

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
NanoViricides, Inc. announces potential treatment option for Ebola Bundibugyo virus strain, highlighting broad-spectrum antiviral drug candidate NV-387, superior to Remdesivir, ready for Phase II clinical trial

NanoViricides NV-387 Clinical Trial Antiviral Drug Ebola Bundibugyo
BRIEF

published on 05/19/2026 at 06:00, 7 days 10 hours ago

NanoViricides Closes $2 Million Registered Direct Offering

Securities NanoViricides Investment Direct Offering Antivirals
PRESS RELEASE

published on 05/19/2026 at 05:55, 7 days 10 hours ago

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces closing of $2M direct offering. Exclusive placement agent D. Boral Capital LLC. SEC registration effective. NV-387, a revolutionary antiviral drug granted Orphan Drug Designation

NanoViricides NV-387 Direct Offering SEC Registration D. Boral Capital LLC
BRIEF

published on 05/18/2026 at 14:35, 8 days 1 hour ago

NanoViricides Highlights NV-387 as a Potential Solution for Ebola Outbreak

NV-387 Antiviral Drug Pandemic Preparedness Ebola Outbreak Bundibugyo Strain
PRESS RELEASE

published on 05/18/2026 at 14:30, 8 days 1 hour ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
NanoViricides, Inc. highlights the urgent need for a broad-spectrum antiviral drug like NV-387 amid an Ebolavirus outbreak in DR Congo and Uganda. NV-387 holds promise as it targets sulfated proteoglycans crucial for viral attachment to cells

NanoViricides NV-387 Antiviral Drug Broad-spectrum Ebolavirus Outbreak
BRIEF

published on 05/15/2026 at 14:40, 11 days 1 hour ago

NanoViricides Announces $2 Million Direct Offering

NanoViricides Securities Offering Direct Investment Institutional Investor Antiviral Technology
PRESS RELEASE

published on 05/15/2026 at 14:35, 11 days 1 hour ago

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces a registered direct offering of common shares and warrants to a fundamental institutional investor for gross proceeds of approximately US$2 million. D. Boral Capital LLC acts as the exclusive placement agent for the Offering

NanoViricides Securities Purchase Agreement Registered Direct Offering D. Boral Capital LLC Fundamental Institutional Investor
BRIEF

published on 05/15/2026 at 14:05, 11 days 2 hours ago

NanoViricides Reports Progress on NV-387 in Latest SEC Filing

NanoViricides NV-387 Phase II Trial Orphan Drug Monkeypox Treatment
PRESS RELEASE

published on 05/15/2026 at 14:00, 11 days 2 hours ago

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
NanoViricides, Inc. files Quarterly Report on Form 10-Q with the SEC. NV-387 advances in Phase II trial for Measles, MPox, and Smallpox treatments. Financial updates disclosed

NV-387 Form 10-Q NanoViricides Inc. Phase II Trial Financial Update

Accesswire

Published on 05/26/2026 at 14:30, 1 hour 45 minutes ago

Klondike Gold Announces 2026 Diamond Drilling Program Underway to Update and Expand Gold Mineral Resources
Published on 05/26/2026 at 14:30, 1 hour 45 minutes ago

Predictiv AI Announces Strategic Healthcare Partnership and CloudRep AI Integration with Clinicmaster Following Successful Multi-Clinic Pilot Deployments
Published on 05/26/2026 at 14:30, 1 hour 45 minutes ago

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
Published on 05/26/2026 at 14:15, 2 hours ago

Worksport (NASDAQ:WKSP) Secures U.S. Patent For 'Industry-First' Zerofrost Heat Pump Through Its Subsidiary, Terravis Energy
Published on 05/26/2026 at 14:00, 2 hours 15 minutes ago

Ameriwest Critical Metals Provides Q2 2026 Corporate Update and Announces Live CEO Investor Webinar

View all ACCESSWIRE

EQS Group

Published on 05/26/2026 at 16:03, 12 minutes ago

EQS-Adhoc: R. Stahl AG: Dr. Claus Bischoff resigns from his office as member of the Management Board of R. STAHL Aktiengesellschaft with immediate effect and will leave the company as of 31 May 2026.
Published on 05/26/2026 at 16:01, 14 minutes ago

EQS-Adhoc: Tempton Personaldienstleistungen GmbH announces full redemption of bonds and the exercise of the early redemption option
Published on 05/26/2026 at 15:37, 38 minutes ago

FGC plans regional rail transport in Catalonia with IVU.rail
Published on 05/26/2026 at 15:25, 49 minutes ago

Amadeus Fire Group: Early extension of the Management Board contract of Dennis Gerlitzki, COO Personnel Services, by further five years
Published on 05/26/2026 at 15:13, 1 hour 2 minutes ago

Annual Report for the 2025 financial year published

Les Echos

Published on 05/26/2026 at 15:00, 1 hour 15 minutes ago

Resolutions Ordinary and Extraordinary General Meetings
Published on 05/26/2026 at 07:59, 8 hours 16 minutes ago

Saint-Gobain has signed an agreement for the sale of its Tiles Distribution business in the Nordics
Published on 05/25/2026 at 17:45, 22 hours 30 minutes ago

Weekly share buyback
Published on 05/22/2026 at 18:05, 3 days 22 hours ago

Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 4 days 3 hours ago

Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026

View all LES ECHOS COMFI WIRE